FDA approves GSK's shingles vaccine: 4 things to know

GlaxoSmithKline on Friday earned Food and Drug Administration approval for its shingles vaccine Shingrix.

Here are four things to know.

1. Shingrix is a nonlive, recombinant subunit Shingles vaccine for adults age 50 and older.

2. The vaccine is administered intramuscularly in two doses.

3. In a recent Phase III clinical trial with more than 38,000 patients, Shingrix had a more than 90 percent efficacy against shingles for all age groups.

4. GlaxoSmithKline expects Shingrix to be available shortly, pending a recommendation from the CDC's Advisory Committee on Immunization Practices.

More articles on supply chain:

Analysis: Biosimilar drugs could cut US healthcare spending by $54B
Health apps should be held to high regulatory scrutiny, researchers say
FDA: 50 medical devices at risk of shortages after Hurricane Maria

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Whitepapers

Featured Webinars